Testing effectiveness (Phase 2)Looking for participantsNCT06854653What this trial is testingPTX 100 in Patients With Relapsed/Refractory CTCLWho this might be right forCTCL Prescient Therapeutics, Ltd. 115
Early research (Phase 1)Looking for participantsNCT06445803What this trial is testingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHLWho this might be right forAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionB-cell Lymphoma Refractory+1 more Rong Tao 48
Testing effectiveness (Phase 2)UnknownNCT04470141What this trial is testingSHC014748M in Patients With Relapsed or Refractory Peripheral T Cell LymphomaWho this might be right forPeripheral T Cell Lymphoma Nanjing Sanhome Pharmaceutical, Co., Ltd. 130
Early research (Phase 1)UnknownNCT04381741What this trial is testingCD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaWho this might be right forDiffuse Large B-cell Lymphoma Second Affiliated Hospital, School of Medicine, Zhejiang University 24
Not applicableStudy completedNCT04833504What this trial is testingClinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell LymphomaWho this might be right forDiffuse Large B-cell LymphomaMantle Cell LymphomaTransformed Follicular Lymphoma+1 more Second Affiliated Hospital, School of Medicine, Zhejiang University 39
Large-scale testing (Phase 3)Not Yet RecruitingNCT05700448What this trial is testingStudy of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaWho this might be right forExtranodal NK/T-cell Lymphoma CStone Pharmaceuticals 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07288814What this trial is testingMitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Who this might be right forRelapsed or Refractory Peripheral T Cell Lymphoma Sun Yat-Sen University Cancer Center 43
Not applicableUnknownNCT05422521What this trial is testingRadiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's LymphomaWho this might be right forRefractory or Relapsed Non-Hodgkin's Lymphoma Centre Hospitalier Universitaire de Nice 20
Not applicableStudy completedNCT02139592What this trial is testingBrentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"Who this might be right forRelapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma Takeda 292
Testing effectiveness (Phase 2)Active Not RecruitingNCT04205409What this trial is testingNivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic MalignanciesWho this might be right forRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more University of Washington 20
Early research (Phase 1)WithdrawnNCT05519527What this trial is testingSTI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWho this might be right forRefractory T Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML) M.D. Anderson Cancer Center
Very early researchUnknownNCT04696705What this trial is testingAllogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsWho this might be right forNon-Hodgkin's Lymphoma (NHL)Peripheral T Cell Lymphoma (PTCL) Institute of Hematology & Blood Diseases Hospital, China 10
Not applicableLooking for participantsNCT06961669What this trial is testingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell LymphomaWho this might be right forLymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM) Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05627856What this trial is testingGNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLWho this might be right forNK/T Cell LymphomaVascular Immunomother T Cell LymphomaNon-Hodgkin Lymphoma Sichuan Baili Pharmaceutical Co., Ltd. 4
Early research (Phase 1)UnknownNCT04012879What this trial is testingStudy Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic LeukemiaWho this might be right forRelapsed Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia Chinese PLA General Hospital 12
Testing effectiveness (Phase 2)UnknownNCT04279379What this trial is testingSintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaWho this might be right forExtranodal NK/T-cell Lymphoma Beijing Tongren Hospital 20
Early research (Phase 1)Active Not RecruitingNCT05665062What this trial is testingAutologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic MalignanciesWho this might be right forCLL/SLLNHLMantle Cell Lymphoma+4 more Synthekine 36
Early research (Phase 1)Study completedNCT00588991What this trial is testingVeliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersWho this might be right forAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT04109482What this trial is testingTrial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.Who this might be right forBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Mustang Bio 3
Not applicableUnknownNCT04447547What this trial is testingClinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin LymphomaWho this might be right forNon-hodgkin's Lymphoma Hebei Senlang Biotechnology Inc., Ltd. 20